论文部分内容阅读
[目的]探讨强肝汤联合胎盘多肽治疗失代偿期乙型肝炎肝硬化患者的疗效。[方法]选取我院2013年8月~2015年3月收治的60例失代偿期乙型肝炎肝硬化患者作为研究对象,并随机分为观察组和对照组,每组各30例。2组患者均给予口服恩替卡韦治疗,观察组在此基础上加以口服中药汤剂强肝汤及静脉注射胎盘多肽注射液治疗,2组均连续治疗48周。2组患者分别于治疗前、治疗12周、治疗24周以及治疗48周时进行乙肝病毒DNA定量(Second liver virus DNA ration,HBV-DNA)、血清丙氨酸氨基转移酶(ALT)、白蛋白(Albumin,ALB)、总胆红素(Total bilirubin,TBIL)检测及Child-Pugh评分,并对各个治疗阶段患者血清HBeAg阴转情况进行比较分析。[结果]观察组治疗12周、24周以及48周后的HBV DNA、ALT、TBIL水平和Child-Pugh评分均明显低于对照组,而ALB水平则明显高于对照组(P<0.05);治疗48周后观察组阴转率为90%,对照组阴转率为66.7%,组间比较观察组阴转率明显高于对照组(P<0.05);治疗后观察组肝腹水患者相比治疗前明显减少,且显著少于对照组,差异均具有统计学意义。[结论]强肝汤联合胎盘多肽治疗失代偿期乙型肝炎肝硬化能有效加强对乙肝病毒复制的抑制作用和对肝功能的改善作用,并因此提高患者治疗后的HBeAg阴转率。
[Objective] To investigate the therapeutic effect of Qianggan Decoction combined with placental polypeptide on patients with decompensated hepatitis B cirrhosis. [Methods] Sixty patients with decompensated hepatitis B cirrhosis admitted in our hospital from August 2013 to March 2015 were selected and randomly divided into observation group and control group, with 30 cases in each group. Two groups of patients were given oral entecavir treatment, the observation group was treated with oral Chinese medicine Decoction Qianggan Decoction and intravenous injection of placental peptide on the basis of the observation group. The two groups were treated continuously for 48 weeks. The two groups were divided into two groups: Second liver virus DNA ration (HBV-DNA), serum alanine aminotransferase (ALT), albumin Albumin (ALB), total bilirubin (TBIL) and Child-Pugh score were measured. The serum HBeAg negative cases in all treatment stages were compared and analyzed. [Results] The levels of HBV DNA, ALT, TBIL and Child - Pugh scores in observation group after 12 weeks, 24 weeks and 48 weeks were significantly lower than those in control group, while ALB levels were significantly higher than those in control group (P <0.05). After 48 weeks of treatment, the negative conversion rate of the observation group was 90% and that of the control group was 66.7%. The negative conversion rate of the observation group was significantly higher than that of the control group (P <0.05) Significantly reduced before treatment, and significantly less than the control group, the differences were statistically significant. [Conclusion] Qianggan Decoction combined with placental polypeptide in decompensated hepatitis B cirrhosis can effectively enhance the inhibitory effect on hepatitis B virus replication and improve the liver function, and thus improve the HBeAg negative conversion rate after treatment.